Johnson & Johnson Announces Updated Results From The Investigational Phase 1b Trimm-2 Study Evaluating The Combination Of TALVEY And DARZALEX FASPRO Based Combination Shows Deep And Durable Responses In Patients With Relapsed Or Refractory Multiple...
Johnson & Johnson Announces Updated Results From The Investigational Phase 1b Trimm-2 Study Evaluating The Combination Of TALVEY And DARZALEX FASPRO Based Combination Shows Deep And Durable Responses In Patients With Relapsed Or Refractory Multiple...
The results from the Phase 1b TRIMM-2 study evaluating TALVEY, the first bispecific T-cell engager to target GPRC5D, combined with DARZALEX Johnson & Johnson Announces Updated Results From The Investigational Phase 1b Trimm-2 Study Evaluating The Combination Of TALVEY And DARZALEX FASPRO Based Combination Shows Deep And Durable Responses In Patients With Relapsed Or Refractory Multiple Myeloma
強生公司宣佈了來自評估TALVEY和DARZALEX FASPRO聯合應用的TRIMm-2研究的最新結果，表明該組合在複發性或難治性多發性骨髓瘤患者中顯示出深層和持久的反應
Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
更新的數據顯示，每週服藥的患者總體反應率達到100％，其中56％的患者達到完全緩解或更好的水平，支持GPRC5D雙特異性抗體的可組合性
Safety profile, including infection rates, similar to TALVEY and DARZALEX FASPRO monotherapies
安全性資料，包括感染率，與TALVEY和DARZALEX FASPRO單藥療法相似
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY (talquetamab-tgvs) with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated an overall response rate (ORR) of 82 percent, further supporting the investigation of this combination. These data were featured in an oral presentation at the 2024 International Myeloma Society Annual Meeting (Abstract #OA – 01).
2024年9月27日，里約熱內盧／美通社——強生公司（紐交所：JNJ）今天宣佈了TRIMm-2研究的最新結果，評估了TALVEY（talquetamab-tgvs）與DARZALEX FASPRO（daratumumab和透明質酸酶-fihj）以及潑他莫單抗（pomalidomide）聯合用於複發性或難治性多發性骨髓瘤患者，展示出82％的總體反應率（ORR），進一步支持這種組合療法的研究。這些數據在2024年國際多發性骨髓瘤學會年會（摘要＃OA - 01）的口頭報告中展示
The results from the Phase 1b TRIMM-2 study evaluating TALVEY, the first bispecific T-cell engager to target GPRC5D, combined with DARZALEX FASPRO, the first subcutaneous anti-CD38 monoclonal antibody, and pomalidomide included patients who received at least three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), or were double refractory to a PI and IMiD and had not received anti-CD38 therapy in the previous 90 days.1
評估TALVEY的TRIMm-2研究結果顯示，這是首個針對GPRC5D的雙特異性T細胞促活劑，與DARZALEX FASPRO，首個皮下抗CD38單克隆抗體，以及潑他莫單抗聯合使用。這包括接受至少三線療法，包括蛋白酶體抑制劑（PI）和免疫調節藥物（IMiD）的患者，或雙重耐受PI和IMiD，且在過去90天內未接受抗CD38治療的患者
At data cutoff, 77 patients had received TALVEY in doses of 0.4 mg/kg weekly (QW) or 0.8 mg/kg biweekly (Q2W), with step-up doses, combined with DARZALEX FASPRO and pomalidomide. In the QW arm (n=18), the overall response rate (ORR) was 100 percent, with 56 percent having a complete response (CR) or better. The Q2W arm (n=59) achieved 76 percent ORR, with 56 percent achieving CR or better. The median duration of response (DOR) in the Q2W arm was 26.4 months, and the median progression-free survival (PFS) was 20.3 months. Results showed 52 percent of patients who are anti-CD38 refractory (n=64) achieved CR or better and 70.8 percent of patients who received prior chimeric antigen receptor T cell (CAR-T) therapy (n=24) achieved CR or better. Patients who had received prior bispecific antibodies (n=29) achieved an 82.8 percent ORR.1
在截至日期，有77名患者接受了TALVEY的每週0.4mg/kg或雙週0.8mg/kg的遞增劑量，與DARZALEX FASPRO和潑他莫單抗聯合使用。在每週劑量組（n=18）中，總體反應率（ORR）爲100％，其中56％達到完全緩解（CR）或更好。雙週劑量組（n=59）達到76％ORR，其中56％達到CR或更好。雙週劑量組中的反應持續時間（DOR）爲26.4個月，無進展生存時間（PFS）中位數爲20.3個月。結果顯示，64名抗CD38耐藥患者中有52％達到CR或更好，24名接受過CAR-T細胞治療的患者中有70.8％達到CR或更好，29名先前接受過雙特異性抗體的患者中82.8％的ORR
譯文內容由第三人軟體翻譯。